Jee Hyun Kong

1.0k total citations
56 papers, 643 citations indexed

About

Jee Hyun Kong is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Jee Hyun Kong has authored 56 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 24 papers in Genetics and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Jee Hyun Kong's work include Chronic Myeloid Leukemia Treatments (19 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Lymphoma Diagnosis and Treatment (12 papers). Jee Hyun Kong is often cited by papers focused on Chronic Myeloid Leukemia Treatments (19 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Lymphoma Diagnosis and Treatment (12 papers). Jee Hyun Kong collaborates with scholars based in South Korea, United States and Japan. Jee Hyun Kong's co-authors include Jean M. Mitchell, Kevin A. Schulman, Kwang Yong Shim, Jong In Lee, Young Woo Eom, Hyun Soo Kim, Ji-Eun Oh, Soon Koo Baik, Ki‐Jong Rhee and Yong Man Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jee Hyun Kong

52 papers receiving 635 citations

Peers

Countries citing papers authored by Jee Hyun Kong

Since Specialization

Citations

This map shows the geographic impact of Jee Hyun Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jee Hyun Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jee Hyun Kong more than expected).

Fields of papers citing papers by Jee Hyun Kong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jee Hyun Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jee Hyun Kong. The network helps show where Jee Hyun Kong may publish in the future.

Co-authorship network of co-authors of Jee Hyun Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Jee Hyun Kong. A scholar is included among the top collaborators of Jee Hyun Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jee Hyun Kong. Jee Hyun Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study 2025 ·Therapeutic Advances in Hematology ·(unknown), Jee Hyun Kong, Junshik Hong, Ja Min Byun, (unknown), Youngil Koh, In Ho Kim, Jinny Park, Young Rok, Jeong‐Ah Kim, Won Seog Kim, Ho‐Jin Shin, Sung Soo Yoon	2
2	Physiologically based pharmacokinetic modeling for umbelliferone in rats and humans: impact of extrahepatic phase II metabolism and hepatic/gut first-pass extraction on oral bioavailability and systemic disposition 2025 ·Journal of Pharmaceutical Investigation ·Jee Hyun Kong, (unknown), Tae Young Kim, Hyung Ryong Moon, Jin‐Wook Yoo, Min‐Soo Kim, Hwayoung Yun, Seonghwan Hwang, Ee Taek Hwang, Yunjin Jung, In‐Soo Yoon	1
3	Glofitamab combined with poseltinib and lenalidomide for relapsed/refractory diffuse large B cell lymphoma: Interim analysis of GPL study. 2024 ·Journal of Clinical Oncology ·Young‐Il Koh, Ja Min Byun, Junshik Hong, Sung-Nam Lim, (unknown), Jee Hyun Kong, Gyeong‐Won Lee, Hyo Jung Kim, (unknown), (unknown), (unknown), Dok Hyun Yoon, Kwai Han Yoo, (unknown), Deok‐Hwan Yang, Jae‐Yong Kwak, (unknown), Ka‐Won Kang, Dong Won Baek, Sung‐Soo Yoon	2
4	Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea 2023 ·Journal of Korean Medical Science ·Jin Seok Kim, Jun Ho Jang, Deog‐Yeon Jo, (unknown), Sung‐Soo Yoon, Je‐Hwan Lee, Sung‐Hyun Kim, Chul Won Choi, Ho‐Jin Shin, Min Kyoung Kim, Jae Hoon Lee, Yeung‐Chul Mun, Jee Hyun Kong, (unknown), (unknown), (unknown), (unknown), (unknown), Jong Wook Lee	3
5	A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea 2023 ·Expert Opinion on Biological Therapy ·Jae‐Cheol Jo, Young‐Woo Jeon, (unknown), Deok‐Hwan Yang, Won Sik Lee, (unknown), Jun Ho Yi, Dok Hyun Yoon, Jee Hyun Kong, Jung‐Yoon Choe, (unknown), (unknown), (unknown), (unknown), (unknown), Seok‐Goo Cho	1
6	Incidence, prevalence and clinical management of achalasia since the introduction of high‐resolution manometry in Western Australia 2023 ·Internal Medicine Journal ·Madoka Inoue, (unknown), (unknown), (unknown), Jee Hyun Kong, Krish Ragunath	1
7	Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3 2021 ·Leukemia Research ·Sungwoo Park, Eun‐Ji Choi, Hyewon Lee, Deog‐Yeon Jo, Chul Won Jung, Jee Hyun Kong, Hawk Kim	1
8	Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia 2021 ·The Korean Journal of Internal Medicine ·Yundeok Kim, Tae‐Hwa Go, (unknown), Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee, Jee Hyun Kong	10
9	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma 2019 ·BMC Cancer ·Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jung Yong Hong, Ho Sup Lee, Sung Yong Oh, Ho‐Jin Shin, Jee Hyun Kong, Jun Ho Yi, Kana Sakamoto, Young Hyeh Ko, Jooryung Huh, Seung‐Sook Lee, Kengo Takeuchi, Dong‐Yeop Shin, Cheolwon Suh, Won Seog Kim	20
10	Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia 2019 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Shin Young Hyun, (unknown), Seung Taek Lim, Kwang Yong Shim, Jong In Lee, Jee Hyun Kong	6
11	Induction of apoptosis and differentiation by Na/H exchanger 1 modulation in acute myeloid leukemia cells 2019 ·Biochemical and Biophysical Research Communications ·Shin Young Hyun, (unknown), Ji Eun Jang, Haerim Chung, Soo‐Jeong Kim, Jin Seok Kim, Jee Hyun Kong, Kwang Yong Shim, Jong In Lee, Yoo Hong Min, June‐Won Cheong	7
12	Characteristics and survival of patients with atypical chronic myeloid leukemia 2019 ·Blood Research ·Jee Hyun Kong, (unknown), Tae‐Hwa Go, Shin Young Hyun, Kwang Yong Shim	2
13	An uncommon cecal bulge caused by a large appendiceal mucinous neoplasm 2018 ·Gastrointestinal Endoscopy ·(unknown), Jee Hyun Kong, (unknown), (unknown)	1
14	Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors 2017 ·Blood ·Won-Sik Lee, (unknown), Hyeoung‐Joon Kim, Jee Hyun Kong, Young Rok, Jae‐Yong Kwak, Sukjoong Oh, Sung‐Hyun Kim, Jeong‐A Kim, Dae Young Zang, Yeung‐Chul Mun, Young‐Woong Won, Sung‐Eun Lee, Yunsuk Choi, Dong‐Wook Kim	1
15	l-Ascorbic acid 2-phosphate and fibroblast growth factor-2 treatment maintains differentiation potential in bone marrow-derived mesenchymal stem cells through expression of hepatocyte growth factor 2015 ·Growth Factors ·(unknown), Hoon Ryu, Ki‐Jong Rhee, Ji-Eun Oh, Soon Koo Baik, Kwang Yong Shim, Jee Hyun Kong, Shin Young Hyun, (unknown), (unknown), (unknown), Yong Man Kim, Hyun Soo Kim, Young Woo Eom, Jong In Lee	23
16	Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia 2012 ·International Journal of Hematology ·Jee Hyun Kong, Yeung‐Chul Mun, Seonwoo Kim, Hang Seok Choi, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, James Moon, Sang Kyun Sohn, Sung‐Hyun Kim, Chul Won Jung, Dong Hwan Kim	9
17	Clinical Features and Treatment Outcomes of Non-Hodgkin’s Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience 2009 ·Acta Haematologica ·Jina Yun, Seok Jin Kim, (unknown), Jee Hyun Kong, Soo Hyun Lee, Kihyun Kım, Young Hyeh Ko, Won Seog Kim	15
18	Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia 2007 ·Acta Haematologica ·Jee Hyun Kong, Seung-Hyun Yoo, Kyoung Eun Lee, (unknown), (unknown), Sang Min Lee, Hye Jung Chang, Moon Young Choi, Min Sun Cho, Yeung‐Chul Mun, Eunmi Nam, Soon Nam Lee, Chu‐Myong Seong	27
19	Promoter −202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk 2005 ·International Journal of Cancer ·Jin Wook Moon, Yoon Soo Chang, Chul Woo Ahn, (unknown), Ju Hye Shin, Jee Hyun Kong, Young Sam Kim, Joon Chang, Sung Kyu Kim, Hee Jung Kim, Soon Il Kim	27
20	Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. 1997 ·Journal of Clinical Oncology ·Jean M. Mitchell, (unknown), Jee Hyun Kong, Kevin A. Schulman	89

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact